PROTECT Data and Teplizumab in Newly Diagnosed T1D

Oct 25, 2023, 03:27 PM
Headliner
Share
Subscribe
In this episode, hosts discuss data from the PROTECT trial, which examined the effects of teplizumab on beta-cell function in patients with newly diagnosed type 1 diabetes.
Share
Subscribe
Next
SURMOUNT-3 and SURMOUNT-4 Data
Top episodes
Orforglipron, Retatrutide, and Other GLP-1 Updates
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Tirzepatide and the Future of Incretin Therapies, with Timothy Garvey, MD
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Key Updates in ADA Standards of Care—2024
by Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives